These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17907105)

  • 1. Learning from tesaglitazar.
    Bailey CJ
    Diab Vasc Dis Res; 2007 Sep; 4(3):161-2. PubMed ID: 17907105
    [No Abstract]   [Full Text] [Related]  

  • 2. Tesaglitazar.
    Kamber N; Davis TM
    IDrugs; 2005 Nov; 8(11):927-35. PubMed ID: 16254788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.
    Ratner RE; Parikh S; Tou C;
    Diab Vasc Dis Res; 2007 Sep; 4(3):214-21. PubMed ID: 17907111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes.
    Göke B; Gause-Nilsson I; Persson A;
    Diab Vasc Dis Res; 2007 Sep; 4(3):204-13. PubMed ID: 17907110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.
    Wilding JP; Gause-Nilsson I; Persson A;
    Diab Vasc Dis Res; 2007 Sep; 4(3):194-203. PubMed ID: 17907109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats.
    Liao J; Soltani Z; Ebenezer P; Isidro-Carrión AA; Zhang R; Asghar A; Aguilar E; Francis J; Hu X; Ferder L; Reisin E
    Nephron Exp Nephrol; 2010; 114(2):e61-8. PubMed ID: 19887847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment.
    Hamrén B; Björk E; Sunzel M; Karlsson M
    Clin Pharmacol Ther; 2008 Aug; 84(2):228-35. PubMed ID: 18388881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
    Charbonnel B
    Lancet; 2009 Jul; 374(9684):96-8. PubMed ID: 19515412
    [No Abstract]   [Full Text] [Related]  

  • 10. Tesaglitazar: a promising approach in type 2 diabetes.
    Cox SL
    Drugs Today (Barc); 2006 Mar; 42(3):139-46. PubMed ID: 16628256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.
    Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
    Alcohol Clin Exp Res; 2016 Mar; 40(3):553-62. PubMed ID: 26857685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes: assessing the pipeline.
    Lebovitz H
    Atheroscler Suppl; 2006 Apr; 7(1):43-9. PubMed ID: 16504599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.
    Samuelsson S; Johansson S; Halldórsdóttir S; Stenhoff H; Ohman KP
    J Clin Pharmacol; 2006 Sep; 46(9):1017-22. PubMed ID: 16920896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
    Fagerberg B; Edwards S; Halmos T; Lopatynski J; Schuster H; Stender S; Stoa-Birketvedt G; Tonstad S; Halldórsdóttir S; Gause-Nilsson I
    Diabetologia; 2005 Sep; 48(9):1716-25. PubMed ID: 16001233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR Agonists: II. Fenofibrate and Tesaglitazar Alter Behaviors Related to Voluntary Alcohol Consumption.
    Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
    Alcohol Clin Exp Res; 2016 Mar; 40(3):563-71. PubMed ID: 26857541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
    Fagerberg B; Schuster H; Birketvedt GS; Tonstad S; Ohman KP; Gause-Nilsson I;
    Diab Vasc Dis Res; 2007 Sep; 4(3):174-80. PubMed ID: 17907107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
    Zhang BC; Li XK; Che WL; Li WM; Hou L; Wei YD; Xu YW
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.